Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis
Status:
Completed
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the safety, pharmacokinetics, and efficacy of oral
SCY-078 vs. standard-of-care following initial intravenous echinocandin therapy in the
treatment of invasive candidiasis.